Little Green Pharma Past Earnings Performance
Past criteria checks 0/6
Little Green Pharma has been growing earnings at an average annual rate of 6.7%, while the Pharmaceuticals industry saw earnings growing at 47.3% annually. Revenues have been growing at an average rate of 56% per year.
Key information
6.7%
Earnings growth rate
30.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | 56.0% |
| Return on equity | -3.9% |
| Net Margin | -13.5% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Little Green Pharma (ASX:LGP) Has Debt But No Earnings; Should You Worry?
Mar 05
Not Many Are Piling Into Little Green Pharma Ltd (ASX:LGP) Just Yet
Nov 01A Look At The Intrinsic Value Of Little Green Pharma Ltd (ASX:LGP)
May 08Statutory Earnings May Not Be The Best Way To Understand Little Green Pharma's (ASX:LGP) True Position
Sep 06What Type Of Shareholders Make Up Little Green Pharma Ltd's (ASX:LGP) Share Registry?
Feb 11
Revenue & Expenses BreakdownBeta
How Little Green Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 23 | -3 | 13 | 0 |
| 30 Jun 23 | 22 | -6 | 14 | 1 |
| 31 Mar 23 | 20 | -9 | 16 | 1 |
| 31 Mar 22 | 14 | -24 | 26 | 4 |
| 31 Dec 21 | 11 | 13 | 16 | 1 |
| 30 Sep 21 | 9 | 18 | 12 | 0 |
| 30 Jun 21 | 7 | 22 | 8 | -2 |
| 31 Mar 21 | 6 | 9 | 8 | -1 |
| 31 Dec 20 | 5 | -3 | 7 | -1 |
| 30 Sep 20 | 4 | -6 | 7 | 0 |
| 30 Jun 20 | 2 | -9 | 8 | 0 |
| 31 Mar 20 | 2 | -9 | 8 | 0 |
| 31 Dec 19 | 1 | -9 | 7 | 1 |
| 30 Sep 19 | 1 | -7 | 6 | 0 |
| 30 Jun 19 | 0 | -6 | 5 | 0 |
| 30 Jun 18 | 0 | -4 | 2 | 0 |
| 30 Jun 17 | 0 | 0 | 0 | 0 |
Quality Earnings: LGP is currently unprofitable.
Growing Profit Margin: LGP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LGP is unprofitable, but has reduced losses over the past 5 years at a rate of 6.7% per year.
Accelerating Growth: Unable to compare LGP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LGP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16%).
Return on Equity
High ROE: LGP has a negative Return on Equity (-3.89%), as it is currently unprofitable.